title: [A long-term survival case with multiple liver metastases from duodenal gastrointestinal stromal tumor that was drastically reduced by the treatment with imatinib].
abstract: Constitutive activation of c-kit receptor tyrosine kinase is a critical factor in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate (IM), a selective tyrosine kinase inhibitor, has been shown in clinical studies to work against such tumors. But there is little information on whether a combination of IM and surgical treatment can prolong survival in a case of unresectable multiple liver metastases. We report a case of postoperative recurrence of gastrointestinal stromal tumor (GIST) treated by the tyrosine kinase inhibitor IM and surgical treatment. Therefore, we discuss some important implications. This 37-year-old Japanese man underwent a pancreaticoduodenectomy for GIST of the duodenum in January 2003. The postoperative course was good at first, but 3 months after the initial operation, MRI showed multiple liver metastases. The patient was treated with 400 mg of IM once daily with only weak liver dysfunction as a side effect. The initial response to treatment of CR continued for 18 months. Currently, IM is the first-line therapy for non-resectable GISTs. As the mechanisms of recurrence and resistance to imatinib in GIST remain unclear, they should be intensively performed in the sight of both clinical and molecular biological viewpoints. Further examination in more cases of recurrent GIST is also necessary to estimate the effectiveness of treatment with IM.
authors.affiliation: Dept of Digestive Surgery, Kyoto Prefectural University of Medicine.
authors.forename: Chouhei
authors.initials: C
authors.lastname: Sakakura
authors.forename: Koji
authors.initials: K
authors.lastname: Miyagawa
authors.forename: Ken-ichiro
authors.initials: K
authors.lastname: Fukuda
authors.forename: Shuichi
authors.initials: S
authors.lastname: Kin
authors.forename: Yuen
authors.initials: Y
authors.lastname: Nakase
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kuriu
authors.forename: Susumu
authors.initials: S
authors.lastname: Nakashima
authors.forename: Tetsuji
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Nobuki
authors.initials: N
authors.lastname: Yamaoka
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Sagara
authors.forename: Akeo
authors.initials: A
authors.lastname: Hagiwara
authors.forename: Hisakazu
authors.initials: H
authors.lastname: Yamagishi
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D003131:Combined Modality Therapy; D004379:Duodenal Neoplasms / Q000473:pathology* / Q000601:surgery; D046152:Gastrointestinal Stromal Tumors / Q000473:pathology* / Q000601:surgery; D006801:Humans; D000068877:Imatinib Mesylate; D008113:Liver Neoplasms / Q000556:secondary* / Q000628:therapy*; D008297:Male; D016577:Pancreaticoduodenectomy; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate